Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06998056 · ClinicalTrials.gov registry record · Phase 2
Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis
A Phase 2 study, sponsored by Arcutis Biotherapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 101
- Enrollment target
NCT06998056 is a Phase 2 study that has completed, run by Arcutis Biotherapeutics. The registered enrollment target is 101 participants.
The verdict
NCT06998056, a Phase 2 study, has completed, sponsored by Arcutis Biotherapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 101 participants
- Enrollment target
Study Summary
This study will assess the safety and tolerability of ARQ-151 cream 0.05% applied once a day for 4 weeks in infants with atopic dermatitis (eczema).
Interventions
- DRUG ARQ-151 cream 0.05%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2025-06-09 |
| Est. Completion | 2025-12-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06998056
The ClinicalTrials.gov registry entry for NCT06998056 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arcutis Biotherapeutics, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ARQ-151 cream 0.05% is the first listed.
NCT06998056 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06998056 about?
NCT06998056 is a clinical study titled "Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis". This study will assess the safety and tolerability of ARQ-151 cream 0.05% applied once a day for 4 weeks in infants with atopic dermatitis (eczema).
What is the current status of trial NCT06998056?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 101 participants. The study started on 2025-06-09. Estimated completion is 2025-12-04.
What interventions are being tested in trial NCT06998056?
The interventions under investigation include: ARQ-151 cream 0.05% (DRUG).
Who is sponsoring clinical trial NCT06998056?
This trial is sponsored by Arcutis Biotherapeutics, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.